{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:27:01Z","timestamp":1791415621791,"version":"4.3.3"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T00:00:00Z","timestamp":1727136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003052","name":"Ministry of Trade, Industry and Energy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["HN22C0203"],"award-info":[{"award-number":["HN22C0203"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["RS-2022-RD010230"],"award-info":[{"award-number":["RS-2022-RD010230"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003627","name":"Rural Development Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003627","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004080","name":"Korea Drug Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004080","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.biopha.2024.117501","type":"journal-article","created":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T05:08:35Z","timestamp":1727932115000},"page":"117501","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["New peripherally-restricted CB1 receptor antagonists, PMG-505\u2013010 and \u2212013 ameliorate obesity-associated NAFLD and fibrosis"],"prefix":"10.1016","volume":"180","author":[{"given":"Hyekyung","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miey","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Hye","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bokyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Sang","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyeal","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Younghoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8353-3619","authenticated-orcid":false,"given":"Hae-Jeung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9415-9965","authenticated-orcid":false,"given":"Cheol-Young","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2024.117501_bib1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2024.117501_bib2","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2024.117501_bib3","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2036.2011.04724.x","article-title":"Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults","volume":"34","author":"Vernon","year":"2011","journal-title":"Aliment Pharm. Ther."},{"key":"10.1016\/j.biopha.2024.117501_bib4","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2741\/4892","article-title":"Current treatment paradigms and emerging therapies for NAFLD\/NASH","volume":"26","author":"Raza","year":"2021","journal-title":"Front Biosci. (Landmark Ed. )"},{"key":"10.1016\/j.biopha.2024.117501_bib5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.tem.2006.11.006","article-title":"Endocannabinoids and the control of energy balance","volume":"18","author":"Matias","year":"2007","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2024.117501_bib6","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.phrs.2009.04.004","article-title":"The endocannabinoid system: role in glucose and energy metabolism","volume":"60","author":"Nogueiras","year":"2009","journal-title":"Pharm. Res"},{"key":"10.1016\/j.biopha.2024.117501_bib7","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1523\/JNEUROSCI.11-02-00563.1991","article-title":"Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study","volume":"11","author":"Herkenham","year":"1991","journal-title":"J. Neurosci."},{"key":"10.1016\/j.biopha.2024.117501_bib8","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1172\/JCI200523057","article-title":"Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity","volume":"115","author":"Osei-Hyiaman","year":"2005","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.biopha.2024.117501_bib9","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/89953","article-title":"Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis","volume":"7","author":"B\u00e1tkai","year":"2001","journal-title":"Nat. Med"},{"key":"10.1016\/j.biopha.2024.117501_bib10","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1124\/mol.63.4.908","article-title":"The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa\/fa rats and in cultured adipocyte cells","volume":"63","author":"Bensaid","year":"2003","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2024.117501_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21207693","article-title":"Cannabinoid receptors: an update on cell signaling, pathophysiological roles and therapeutic opportunities in neurological, cardiovascular, and inflammatory diseases","volume":"21","author":"Haspula","year":"2020","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.biopha.2024.117501_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22179472","article-title":"The endocannabinoid system: a potential target for the treatment of various diseases","volume":"22","author":"Lowe","year":"2021","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.biopha.2024.117501_bib13","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.jhep.2013.03.032","article-title":"Cannabinoid signaling and liver therapeutics","volume":"59","author":"Mallat","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2024.117501_bib14","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/13543776.2019.1597851","article-title":"A patent update on cannabinoid receptor 1 antagonists (2015-2018)","volume":"29","author":"Amato","year":"2019","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.biopha.2024.117501_bib15","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0140-6736(05)66374-X","article-title":"Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study","volume":"365","author":"Van Gaal","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2024.117501_bib16","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.amjmed.2006.11.014","article-title":"Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus","volume":"120","author":"Hollander","year":"2007","journal-title":"Am. J. Med"},{"key":"10.1016\/j.biopha.2024.117501_bib17","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/S0140-6736(07)61721-8","article-title":"Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials","volume":"370","author":"Christensen","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2024.117501_bib18","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cmet.2012.07.002","article-title":"Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance","volume":"16","author":"Tam","year":"2012","journal-title":"Cell Metab."},{"key":"10.1016\/j.biopha.2024.117501_bib19","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1021\/acsptsci.1c00048","article-title":"Functional selectivity of a biased Cannabinoid-1 Receptor (CB1R) Antagonist","volume":"4","author":"Liu","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.biopha.2024.117501_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fneph.2023.1138416","article-title":"Therapeutic potential of a novel peripherally restricted CB1R inverse agonist on the progression of diabetic nephropathy","volume":"3","author":"Jacquot","year":"2023","journal-title":"Front Nephrol."},{"key":"10.1016\/j.biopha.2024.117501_bib21","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/dom.15353","article-title":"Effects of CB1R inverse agonist, INV-202, in patients with features of metabolic syndrome. A randomized, placebo-controlled, double-blind phase 1b study","volume":"26","author":"Crater","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.biopha.2024.117501_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107477","article-title":"The therapeutic potential of second and third generation CB(1)R antagonists.","volume":"208","author":"Cinar","year":"2020","journal-title":"Pharm. Ther."},{"key":"10.1016\/j.biopha.2024.117501_bib23","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.87336","article-title":"Hybrid inhibitor of peripheral cannabinoid-1 receptors and inducible nitric oxide synthase mitigates liver fibrosis","volume":"1","author":"Cinar","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.biopha.2024.117501_bib24","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.tips.2015.05.001","article-title":"Nitric oxide in liver diseases","volume":"36","author":"Iwakiri","year":"2015","journal-title":"Trends Pharm. Sci."},{"key":"10.1016\/j.biopha.2024.117501_bib25","doi-asserted-by":"crossref","DOI":"10.1172\/JCI152242","article-title":"Cannabinoid receptor 1 signaling in hepatocytes and stellate cells does not contribute to NAFLD","volume":"131","author":"Wang","year":"2021","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.biopha.2024.117501_bib26","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.2174\/1568026619666190708164841","article-title":"Overcoming the psychiatric side effects of the cannabinoid CB1 receptor antagonists: current approaches for therapeutics development","volume":"19","author":"Nguyen","year":"2019","journal-title":"Curr. Top. Med Chem."},{"key":"10.1016\/j.biopha.2024.117501_bib27","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.cell.2016.10.004","article-title":"Crystal structure of the human cannabinoid receptor CB(1).","volume":"167","author":"Hua","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2024.117501_bib28","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/365061a0","article-title":"Molecular characterization of a peripheral receptor for cannabinoids","volume":"365","author":"Munro","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2024.117501_bib29","doi-asserted-by":"crossref","first-page":"E174","DOI":"10.1152\/ajpendo.00338.2017","article-title":"Endocannabinoids in the Islets of Langerhans: the ugly, the bad, and the good facts","volume":"315","author":"Gonz\u00e1lez-Mariscal","year":"2018","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2024.117501_bib30","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1111\/jcmm.13523","article-title":"Blockade of cannabinoid 1 receptor improves glucose responsiveness in pancreatic beta cells","volume":"22","author":"Shin","year":"2018","journal-title":"J. Cell Mol. Med"},{"key":"10.1016\/j.biopha.2024.117501_bib31","article-title":"The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research","volume":"18","author":"Percie du Sert","year":"2020","journal-title":"PLoS Biol."},{"key":"10.1016\/j.biopha.2024.117501_bib32","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jchromb.2008.01.020","article-title":"Determination of endocannabinoid receptor antagonist SR141716 (rimonabant) in plasma by liquid chromatograph tandem mass spectrometry","volume":"863","author":"McCulloch","year":"2008","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.biopha.2024.117501_bib33","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0021-9258(18)64849-5","article-title":"GH. A simple method for the isolation and purification of total lipides from animal tissues","volume":"226","author":"Folch","year":"1957","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2024.117501_bib34","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jgr.2019.09.004","article-title":"Ameliorative effects of black ginseng on nonalcoholic fatty liver disease in free fatty acid-induced HepG2 cells and high-fat\/high-fructose diet-fed mice","volume":"44","author":"Park","year":"2020","journal-title":"J. Ginseng Res"},{"key":"10.1016\/j.biopha.2024.117501_bib35","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0003-2697(79)90738-3","article-title":"Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction","volume":"95","author":"Ohkawa","year":"1979","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.biopha.2024.117501_bib36","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/j.1365-2559.2012.04193.x","article-title":"Quantifying hepatic steatosis - more than meets the eye","volume":"60","author":"Levene","year":"2012","journal-title":"Histopathology"},{"key":"10.1016\/j.biopha.2024.117501_bib37","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/BF01002772","article-title":"Picrosirius staining plus polarization microscopy, a specific method for collagen detection in tissue sections","volume":"11","author":"Junqueira","year":"1979","journal-title":"Histochem J."},{"key":"10.1016\/j.biopha.2024.117501_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0206152","article-title":"CB1 receptor blockade ameliorates hepatic fat infiltration and inflammation and increases Nrf2-AMPK pathway in a rat model of severely uncontrolled diabetes","volume":"13","author":"Chang","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2024.117501_bib39","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1177\/0271678X16642233","article-title":"Blood-brain barrier breakdown promotes macrophage infiltration and cognitive impairment in leptin receptor-deficient mice","volume":"36","author":"Stranahan","year":"2016","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"10.1016\/j.biopha.2024.117501_bib40","article-title":"Novel peripherally restricted cannabinoid 1 receptor selective antagonist TXX-522 with prominent weight-loss efficacy in diet induced obese mice","volume":"8","author":"Chen","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2024.117501_bib41","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s41386-020-00876-5","article-title":"A novel allosteric modulator of the cannabinoid CB(1) receptor ameliorates hyperdopaminergia endophenotypes in rodent models.","volume":"46","author":"Mielnik","year":"2021","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopha.2024.117501_bib42","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1515\/jbcpp-2015-0096","article-title":"CB1 cannabinoid receptor-mediated increases in cyclic AMP accumulation are correlated with reduced Gi\/o function","volume":"27","author":"Eldeeb","year":"2016","journal-title":"J. Basic Clin. Physiol. Pharm."},{"key":"10.1016\/j.biopha.2024.117501_bib43","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1590\/2359-3997000000272","article-title":"Glycated albumin: a potential biomarker in diabetes","volume":"61","author":"Freitas","year":"2017","journal-title":"Arch. Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2024.117501_bib44","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1002\/hep.28970","article-title":"Malondialdehyde epitopes are sterile mediators of hepatic inflammation in hypercholesterolemic mice","volume":"65","author":"Busch","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2024.117501_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.880298","article-title":"Association of inflammatory cytokines with non-alcoholic fatty liver disease","volume":"13","author":"Duan","year":"2022","journal-title":"Front Immunol."},{"key":"10.1016\/j.biopha.2024.117501_bib46","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1053\/j.gastro.2019.11.311","article-title":"Mechanisms of fibrosis development in nonalcoholic steatohepatitis","volume":"158","author":"Schwabe","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2024.117501_bib47","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1002\/hep.22278","article-title":"Lack of inducible nitric oxide synthase leads to increased hepatic apoptosis and decreased fibrosis in mice after chronic carbon tetrachloride administration","volume":"47","author":"Aram","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2024.117501_bib48","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/labinvest.2015.67","article-title":"The role of iNOS in cholesterol-induced liver fibrosis","volume":"95","author":"Anavi","year":"2015","journal-title":"Lab Invest"},{"key":"10.1016\/j.biopha.2024.117501_bib49","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/j.1524-475X.2007.00308.x","article-title":"New strategy for the antifibrotic therapy with oral administration of FR260330 (a selective inducible nitric oxide synthase inhibitor) in rat experimental liver cirrhosis","volume":"15","author":"Kikuchi","year":"2007","journal-title":"Wound Repair Regen."},{"key":"10.1016\/j.biopha.2024.117501_bib50","doi-asserted-by":"crossref","first-page":"30919","DOI":"10.1039\/C8RA04955F","article-title":"SKLB023 as an iNOS inhibitor alleviated liver fibrosis by inhibiting the TGF-beta\/Smad signaling pathway","volume":"8","author":"Zhang","year":"2018","journal-title":"RSC Adv."},{"key":"10.1016\/j.biopha.2024.117501_bib51","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1172\/JCI42551","article-title":"Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity","volume":"120","author":"Tam","year":"2010","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.biopha.2024.117501_bib52","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1096\/fj.201801152RR","article-title":"A novel peripheral cannabinoid 1 receptor antagonist, AJ5012, improves metabolic outcomes and suppresses adipose tissue inflammation in obese mice","volume":"33","author":"Han","year":"2019","journal-title":"Faseb J."},{"key":"10.1016\/j.biopha.2024.117501_bib53","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1021\/acsptsci.0c00213","article-title":"Peripherally selective CB1 receptor antagonist improves symptoms of metabolic syndrome in mice","volume":"4","author":"Khan","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.biopha.2024.117501_bib54","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.2337\/db08-0161","article-title":"Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats","volume":"57","author":"Nogueiras","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2024.117501_bib55","doi-asserted-by":"crossref","first-page":"R345","DOI":"10.1152\/ajpregu.00545.2002","article-title":"Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice","volume":"284","author":"Ravinet Trillou","year":"2003","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.biopha.2024.117501_bib56","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.biopha.2024.117501_bib57","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/hep.21641","article-title":"Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa\/fa rats","volume":"46","author":"Gary-Bobo","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2024.117501_bib58","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1172\/JCI34827","article-title":"Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice","volume":"118","author":"Osei-Hyiaman","year":"2008","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.biopha.2024.117501_bib59","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nm1421","article-title":"CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis","volume":"12","author":"Teixeira-Clerc","year":"2006","journal-title":"Nat. Med"},{"key":"10.1016\/j.biopha.2024.117501_bib60","doi-asserted-by":"crossref","first-page":"926","DOI":"10.2337\/db09-1482","article-title":"CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice","volume":"59","author":"Jourdan","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2024.117501_bib61","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1161\/ATVBAHA.108.176362","article-title":"Effect of rimonabant on the high-triglyceride\/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial","volume":"29","author":"Despr\u00e9s","year":"2009","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.biopha.2024.117501_bib62","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/j.1742-1241.2011.02683.x","article-title":"Rimonabant improves cholesterol, insulin resistance and markers of non-alcoholic fatty liver in morbidly obese patients: a retrospective cohort study","volume":"65","author":"Wierzbicki","year":"2011","journal-title":"Int J. Clin. Pr."},{"key":"10.1016\/j.biopha.2024.117501_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101087","article-title":"Reversal of diet-induced hepatic steatosis by peripheral CB1 receptor blockade in mice is p53\/miRNA-22\/SIRT1\/PPAR\u03b1 dependent","volume":"42","author":"Azar","year":"2020","journal-title":"Mol. Metab."},{"key":"10.1016\/j.biopha.2024.117501_bib64","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1111\/bph.15010","article-title":"The peripheral CB(1) receptor antagonist JD5037 attenuates liver fibrosis via a CB(1) receptor\/\u03b2-arrestin1\/Akt pathway","volume":"177","author":"Tan","year":"2020","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.biopha.2024.117501_bib65","doi-asserted-by":"crossref","first-page":"993","DOI":"10.2353\/ajpath.2008.070720","article-title":"Prevention of hepatic fibrosis in a murine model of metabolic syndrome with nonalcoholic steatohepatitis","volume":"173","author":"DeLeve","year":"2008","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.biopha.2024.117501_bib66","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.molmet.2017.08.011","article-title":"Decreasing CB(1) receptor signaling in Kupffer cells improves insulin sensitivity in obese mice.","volume":"6","author":"Jourdan","year":"2017","journal-title":"Mol. Metab."},{"key":"10.1016\/j.biopha.2024.117501_bib67","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1021\/jf403286w","article-title":"Resveratrol attenuates high-fat diet-induced disruption of the blood-brain barrier and protects brain neurons from apoptotic insults","volume":"62","author":"Chang","year":"2014","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.biopha.2024.117501_bib68","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1093\/ntr\/ntv044","article-title":"Nicotine attenuates disruption of blood-brain barrier induced by saturated-fat feeding in wild-type mice","volume":"17","author":"Elahy","year":"2015","journal-title":"Nicotine Tob. Res"},{"key":"10.1016\/j.biopha.2024.117501_bib69","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.physbeh.2012.05.015","article-title":"The effects of a high-energy diet on hippocampal-dependent discrimination performance and blood-brain barrier integrity differ for diet-induced obese and diet-resistant rats","volume":"107","author":"Davidson","year":"2012","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.biopha.2024.117501_bib70","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/jcbfm.2013.166","article-title":"Diet-induced obesity suppresses expression of many proteins at the blood-brain barrier","volume":"34","author":"Ouyang","year":"2014","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"10.1016\/j.biopha.2024.117501_bib71","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3389\/fnut.2018.00131","article-title":"Effect of Hypoproteic and High-Fat Diets on Hippocampal Blood-Brain Barrier Permeability and Oxidative Stress","volume":"5","author":"de Aquino","year":"2018","journal-title":"Front Nutr."},{"key":"10.1016\/j.biopha.2024.117501_bib72","doi-asserted-by":"crossref","first-page":"H1","DOI":"10.1530\/VB-19-0033","article-title":"Immune cell trafficking across the blood-brain barrier in the absence and presence of neuroinflammation","volume":"2","author":"Marchetti","year":"2020","journal-title":"Vasc. Biol."},{"key":"10.1016\/j.biopha.2024.117501_bib73","article-title":"Prolonged High-Fat Diet Consumption throughout Adulthood in Mice Induced Neurobehavioral Deterioration via Gut-Brain Axis","volume":"15","author":"Wu","year":"2023","journal-title":"Nutrients"},{"key":"10.1016\/j.biopha.2024.117501_bib74","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.bbi.2021.11.018","article-title":"Long-term high-fat diet consumption by mice throughout adulthood induces neurobehavioral alterations and hippocampal neuronal remodeling accompanied by augmented microglial lipid accumulation","volume":"100","author":"Zhuang","year":"2022","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.biopha.2024.117501_bib75","doi-asserted-by":"crossref","first-page":"6173","DOI":"10.1016\/j.bmcl.2012.08.004","article-title":"JD-5006 and JD-5037: peripherally restricted (PR) cannabinoid-1 receptor blockers related to SLV-319 (Ibipinabant) as metabolic disorder therapeutics devoid of CNS liabilities","volume":"22","author":"Chorvat","year":"2012","journal-title":"Bioorg. Med Chem. Lett."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224013878?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224013878?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:59:02Z","timestamp":1773968342000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224013878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":75,"alternative-id":["S0753332224013878"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117501","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New peripherally-restricted CB1 receptor antagonists, PMG-505\u2013010 and \u2212013 ameliorate obesity-associated NAFLD and fibrosis","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117501","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117501"}}